Peptide vaccine based on a new universal influenza a hemagglutinin head domain epitope and human monoclonal antibodies binding thereto

Patent metadata

Field	Value
Publication number	US-12496336-B2
Application number	US-202017611564-A
Country	US
Kind code	B2
Filing date	May 16, 2020
Priority date	May 16, 2019
Publication date	Dec 16, 2025
Grant date	Dec 16, 2025

Abstract

The present disclosure is directed to peptide antigens derived from a previously undefined epitope on influenza A virus hemagglutinin and methods for use thereof.

First claim

What is claimed is:

1 . A method of inducing an immune response in a subject infected with influenza A virus or at risk of contracting influenza A virus, comprising delivering to said subject one or more immunogen(s), or one or more RNA(s) or expression vector(s) encoding said immunogen(s), wherein said immunogen(s) is/are selected from peptide(s) SEQ ID NOS: 11-22, 24, 29, and/or 30, or are selected from peptide(s) comprising 95% identity to peptide(s) comprising SEQ ID NOS: 1-10, 23, 25-28, 31 and/or 32.

2 . The method of claim 1 , further comprising administering an adjuvant to said subject.

3 . The method of claim 1 , wherein said immunogen(s) is fused to a non-influenza amino acid sequence.

4 . The method of claim 1 , wherein said immunogen(s) is formulated in a pharmaceutically acceptable buffer, diluent or excipient, or is lyophilized.

5 . The method of claim 1 , wherein said subject is a human subject.

6 . The method of claim 1 , wherein said immune response is a protective immune response or a therapeutic immune response.

7 . The method of claim 1 , wherein said immunogen(s) comprises 2, 3, 4, 5, 6, 7, 8, 9, 10 or more different peptides selected from SEQ ID NOS: 1-32, or are selected from different peptides comprising 95% identity to peptides comprising SEQ ID NOS: 1-10, 23, 25-28, 31 and/or 32.

8 . The method of claim 1 , further comprising delivering said immunogen(s), RNA(s) or expression vector(s) to said subject at least a second time.

9 . The method of claim 1 , further comprising measuring an immune response in said subject after delivery.

10 . The method of claim 1 , wherein said immunogen(s) is/are peptide(s) selected from peptides comprising SEQ ID NOS: 1-32.

11 . The method of claim 1 , wherein said immunogen(s) have 95% identity to one or more peptides selected from peptides comprising SEQ ID NOS: 1-10, 23, 25-28, 31 and/or 32.

12 . The method of claim 10 , wherein said immunogen(s) is/are a multimer of said peptides.

13 . The method of claim 11 , wherein said immunogen(s) is/are a multimer of multiple sequences of said peptides.

14 . The method of claim 1 , wherein said immunogen(s) is/are delivered in a lipid and/or nanoparticulate formulation.

15 . A vaccine formulation comprising one or more immunogen(s), or one or more RNA(s) or expression vector(s) encoding said peptide(s), wherein said immunogen(s) is/are selected from peptide(s) SEQ ID NOS: 11-22, 24, 29, and/or 30, or are selected from peptide(s) comprising 95% identity to peptide(s) comprising SEQ ID NOS: 1-10, 23, 25-28, 31 and/or 32.

16 . The vaccine formulation of claim 15 , further comprising an adjuvant.

17 . The vaccine formulation of claim 15 , wherein said immunogen(s) is/are fused to a non-influenza amino acid sequence.

18 . The vaccine formulation of claim 15 , wherein said immunogen(s) is formulated in a pharmaceutically acceptable buffer, diluent or excipient, or is lyophilized.

19 . The vaccine formulation of claim 15 , wherein said immunogen(s) comprises 2, 3, 4, 5, 6, 7, 8, 9, 10 or more different peptides selected from SEQ ID NOS: 1-32, or are selected from different peptides comprising 95% identity to peptides comprising SEQ ID NOS: 1-10, 23, 25-28, 31 and/or 32.

20 . The vaccine formulation of claim 15 , wherein said immunogen(s) is/are peptide(s) selected from peptides comprising SEQ ID NOS: 1-32.

21 . The vaccine formulation of claim 15 , wherein said immunogen(s) have 95% identity to one or more peptides selected from peptides comprising SEQ ID NOS: 1-10, 23, 25-28, 31 and/or 32.

22 . The vaccine formulation of claim 20 , wherein said immunogen(s) is/are a multimer of said peptides.

23 . The vaccine formulation of claim 21 , wherein said immunogen(s) is/are a multimer of said peptides.

24 . The method of claim 2 , wherein the adjuvant is selected from a water-in-oil or water-in-oil-in-water formulation, a cytokine, or an immune modulator.

25 . The method of claim 5 , wherein said human subject is a child from 6 mos age to 12 years of age.

26 . The method of claim 5 , wherein said human subject is an adult over the age of 60.

27 . The method of claim 16 , wherein the adjuvant is selected from a water-in-oil or water-in-oil-in-water formulation, a cytokine, or an immune modulator.

Assignees

• Univ Vanderbilt
• Scripps Research Inst

Inventors

• Crowe Jr James E
• Hu Xiaozhen
• Schief William

Classifications

• C07K16/108

  Orthomyxoviridae (F), e.g. influenza virus · CPC title

• C12N7/00

  Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title

• A61K2039/575

  humoral response · CPC title

• A61K2039/5252

  inactivated (killed) · CPC title

• A61K2039/505

  comprising antibodies · CPC title